drugset
drugset / Trial / NCT05349097

Study to Evaluate IMG-004 in Healthy Participants

NCT05349097 ↗

Phase 1 Completed 72 enrolled Inmagene LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Orally Administered IMG-004 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) and an Open-Label Study of Single Oral Dose of IMG-004 to Evaluate the Food Effect in Healthy Participants

Timeline

Start
2022-08-08
Primary completion
2024-05-02
Completion
2024-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject IMG-004 Unknown 30 mg Oral
Subject IMG-004 Unknown 50 mg Oral
Subject IMG-004 Unknown 100 mg Oral
Subject IMG-004 Unknown 150 mg Oral
Subject IMG-004 Unknown 200 mg Oral
Subject IMG-004 Unknown 300 mg Oral
Subject IMG-004 Unknown 400 mg Oral
Subject IMG-004 Unknown 600 mg Oral

Indications

No indication recorded.